Any feedback?
Literature summary for 3.4.14.5 extracted from
- Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes (2007), Curr. Med. Res. Opin., 23, 919-931.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | DPP-4 inhibitors are antidiabetogenic drugs, that are effective as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. The DPP-4 inhibitors are well tolerated, carry a low risk of producing hypoglycemia, and are weight-neutral | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | potent and highly specific inhibitor of DPP-4 | Homo sapiens |  |
| vildagliptin | competitive and reversible inhibitor of DPP-4. It is highly specific for DPP-4 relative to other peptidases. Vildagliptin is rapidly and almost completely absorbed following oral administration and inhibits plasma DPP-4 activity by 90% within 30-60 min. DPP-4 activity remains significantly inhibited for more than 12 h following a single dose | Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| DPP-4 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
